Bimagrumab was shown to be effective in an RCT including adults with insulin resistance, demonstrating a -7.9% decrease in fat mass, +2.7% increase in lean mass, and improved HbA1c and insulin sensitivity after 10 weeks of bimagrumab treatment (185). The gene discussed is INS; the disease is Insulin resistance.